BA
Therapeutic Areas
Bayer Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nubeqa® (darolutamide) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase III |
| Kerendia® (finerenone) | Chronic Kidney Disease in Type 2 Diabetes | Phase III |
| Asundexian (BAY 2433334) | Stroke Prevention after Acute Non-Cardioembolic Ischemic Stroke | Phase III |
| BAY 2927088 | NSCLC with EGFR Mutations | Phase I/II |
| BAY 2666605 (JNJ-75276617) | Acute Myeloid Leukemia with NUP98 Rearrangements | Phase I |
| AAV-hFKRP (ASK-010) | Limb-Girdle Muscular Dystrophy Type 2I/R9 | Phase I/II |
| bri-cel (BAY 2413334) | Relapsed/Refractory Multiple Myeloma | Phase I |
| OpRegen® (RG6501) | Geographic Atrophy Secondary to AMD | Phase II |
Leadership Team at Bayer
WN
Wolfgang Nickl
Chief Financial Officer
DC
Dr. Christian Rommel
Head of Research and Development, Pharmaceuticals
DR
Dr. Robert Reiter
Head of R&D, Crop Science
HS
Heiko Schipper
President, Consumer Health
DS
Dr. Sebastian Guth
President, Pharmaceuticals Americas
OK
Oliver Kohlhaas
President, Pharmaceuticals International